Glenmark Pharmaceuticals to launch DCGI-approved BRUKINSA in India for treatment of hematological malignancies
Globally, BRUKINSA is approved in more than 70 countries
Globally, BRUKINSA is approved in more than 70 countries
Oxcarbazepine ER Tablets (RLD Oxtellar XR) had estimated annual sales of US$ 206 million in the US (IQVIA MAT April 2025)
Usnoflast has previously also received ‘Orphan Drug Designation (ODD)’ from the USFDA
Akums invested Rs. 272 crore in capital expenditure during FY25
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
Adjusted Profit After Tax (PAT) for the year ended March 31, 2025 was at Rs. 1,389.4 crore
Record international participation reflects renewed momentum in pharma manufacturing and global sourcing, as easing tariffs fuel growth
Certification bolsters Venus Remedies' position in PIC/S markets, reinforcing commitment to global quality standards
This global affiliation marks a critical step in the company’s mission to create long-term value through ethical practices, scientific innovation, and inclusive healthcare delivery
Subscribe To Our Newsletter & Stay Updated